当前位置:产品中心>单抗/多抗

Anti-Human CD266/TNFRSF12A Reference Antibody|抗人CD266/TNFRSF12A参考抗体(靶标:人TWEAK受体(TNFRSF12A))

货号:RB9T37015023
  • 价格:面议
  • 点击数:726
  

产品介绍

产品参数

形态Liquid
宿主种属Humanized
克隆性Monoclonal
抗体亚型IgG1-kappa
纯度>95% purity as determined by SDS-PAGE.
纯化方式Protein A/G purified from cell culture supernatant.
浓度3.33mg/ml
内毒素水平Please contact the lab for this information.
应用ELISA, Bioactivity: FACS, Functional assay, Research in vivo
种属反应性Human
靶标FGF-inducible 14, TNFRSF12A, FN14, CD266, TweakR, Fibroblast growth factor-inducible immediate-early response protein 14, Tweak-receptor, Tumor necrosis factor receptor superfamily member 12A
储存缓冲液0.01M PBS, pH 7.4.
稳定性和储存Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
表达系统Mammalian Cells
登录号Q9NP84
背景信息Enavatuzumab (PDL192; ABT-361) is a humanized IgG1 monoclonal antibody targeting the receptor of TNF-like weak inducer of apoptosis (TWEAK). TWEAK (Fn14; TNFRSF12A), the natural ligand of the TWEAK receptor (TweakR), stimulates multiple cellular responses. Enavatuzumab induces tumor growth inhibition through direct TweakR signaling and antibody dependent cell-mediated cytotoxicity (ADCC). Enavatuzumab can actively recruits and activates myeloid effectors to kill tumor cells. Enavatuzumab inhibits the growth of various human TweakR-positive cancer cell lines and xenografts in vitro and in vivo .<br>• TWEAK/Fn14 signaling in tumors., PMID:28639899<br/>• The TWEAK/Fn14/CD163 axis-implications for metabolic disease., PMID:34542797<br/>• TWEAK/Fn14 axis in respiratory diseases., PMID:32526219<br/>• TWEAK/Fn14 signalling driven super-enhancer reprogramming promotes pro-metastatic metabolic rewiring in triple-negative breast cancer., PMID:38965263<br/>• Tumor Necrosis Factor-Like Weak Inducer of Apoptosis (TWEAK)/Fibroblast Growth Factor-Inducible 14 (Fn14) Axis in Cardiovascular Diseases: Progress and Challenges., PMID:32053869<br/>• Role of the TWEAK/Fn14 pathway in autoimmune diseases., PMID:26659091<br/>• TWEAK/Fn14 signaling: a promising target in intervertebral disc degeneration., PMID:26907852<br/>• Controversies in TWEAK-Fn14 signaling in skeletal muscle atrophy and regeneration., PMID:32200423<br/>• Role of tumor necrosis factor-like weak inducer of apoptosis (TWEAK)/fibroblast growth factor-inducible 14 (Fn14) axis in rheumatic diseases., PMID:23106895<br/>• Tumor Necrosis Factor Receptor Mediates Fibroblast Growth Factor-Inducible 14 Signaling., PMID:28934756<br/>
别名PDL192, 1062149-33-0
备注For research use only. Not suitable for clinical or therapeutic use.